Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treating low HDL--from bench to bedside.

Dominic S Ng1

  • 1Department of Medicine, St. Michael's Hospital, Toronto, Ontario, Canada. ngd@smh.toronto.on.ca

Clinical Biochemistry
|August 11, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heterozygous midnolin knockout attenuates severity of nonalcoholic fatty liver disease in mice fed a Western-style diet high in fat, cholesterol, and fructose.

American journal of physiology. Gastrointestinal and liver physiology·2023
Same author

Evolving ANGPTL-based lipid-lowering strategies and beyond.

Current opinion in lipidology·2021
Same author

Emerging insight into the role of cellular cholesterol in the pathogenesis of nonalcoholic steatohepatitis progression.

Current opinion in lipidology·2020
Same author

Lecithin:cholesterol acyltransferase: symposium on 50 years of biomedical research from its discovery to latest findings.

Journal of lipid research·2020
Same author

Novel metabolic phenotypes in lecithin cholesterol acyltyransferase-deficient mice.

Current opinion in lipidology·2018
Same author

Pak1 mediates the stimulatory effect of insulin and curcumin on hepatic ChREBP expression.

Journal of molecular cell biology·2017

High-density lipoprotein cholesterol (HDL-C) is linked to lower coronary heart disease (CHD) risk. This review explores HDL metabolism, its role in atherosclerosis, and emerging HDL-targeted therapies.

Area of Science:

  • Cardiovascular Science
  • Metabolic Research
  • Pharmacology

Background:

  • The inverse relationship between plasma high-density lipoprotein cholesterol (HDL-C) and coronary heart disease (CHD) risk is established.
  • Developing effective HDL-targeting therapeutics is challenging due to HDL's heterogeneity and complex metabolism.
  • HDL plays a crucial role in reverse cholesterol transport and preventing atherogenesis.

Purpose of the Study:

  • To review recent advances in understanding HDL metabolism and its role in atherogenesis.
  • To discuss current lipid-modifying drugs and novel therapeutic strategies targeting HDL.
  • To provide an overview of the therapeutic landscape for modulating HDL-C levels.

Main Methods:

  • Literature review of recent scientific publications.

Related Experiment Videos

  • Analysis of existing data on lipid-modifying drugs and HDL-targeted therapies.
  • Synthesis of information on HDL metabolism and its implications in cardiovascular disease.

    • Main Results:

    • Current lipid-modifying drugs demonstrate varying effects on HDL-C levels.
    • Novel therapeutic strategies are under development to specifically target HDL function and metabolism.
    • Understanding HDL heterogeneity is key to developing effective treatments.

    Conclusions:

    • Effective HDL-targeted therapies remain a significant goal in cardiovascular disease prevention.
    • Further research into HDL metabolism and composition is essential for therapeutic advancements.
    • A combination of existing and novel strategies may be necessary to optimize HDL-C levels and reduce CHD risk.